Bank Of New York Mellon Corp Hepion Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.31 - $1.06 $27,501 - $94,037	88,715 New	88,715 $68.9 Million
Q4 2022 Feb 14, 2023	BUY	$0.27 - $11.9 $23,953 - $1.06 Million	88,715 New	88,715 $26,000
Q2 2022 Aug 15, 2022	SELL	$0.57 - $1.22 $100 - $215	-177 Reduced 0.11%	158,217 $91,000
Q4 2021 Feb 11, 2022	BUY	$1.14 - $1.58 $79,002 - $109,494	69,300 Added 77.78%	158,394 $181,000
Q3 2021 Nov 12, 2021	BUY	$1.39 - $2.1 $62,925 - $95,067	45,270 Added 103.3%	89,094 $136,000
Q2 2021 Aug 11, 2021	SELL	$1.56 - $2.26 $7,453 - $10,798	-4,778 Reduced 9.83%	43,824 $86,000
Q1 2021 May 13, 2021	BUY	$1.77 - $2.98 $13,552 - $22,817	7,657 Added 18.7%	48,602 $89,000
Q4 2020 Feb 09, 2021	BUY	$1.58 - $3.64 $64,693 - $149,039	40,945 New	40,945 $89,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $45.7M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.